Brief: Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis
08/12/2025 12:33
Dec 8 (Reuters) - Cogent Biosciences Inc COGT.O: COGENT BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF APEX TRIAL OF BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COGENT BIOSCIENCES INC - APEX NDA SUBMISSION EXPECTED IN 1H 2026 COGENT BIOSCIENCES INC - BEZUCLASTINIB TRIAL SHOWED 89% OF PATIENTS ACHIEVING ≥50% REDUCTION IN BONE MARROW MAST CELLS Source text: ID:nGNX7299pC Further company coverage: COGT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's